Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
about
Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma.Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum.Receptor-type protein tyrosine phosphatases in cancer.MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data.Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.
P2860
Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Aberrant PTPRO methylation in ...... mes in breast cancer patients.
@ast
Aberrant PTPRO methylation in ...... mes in breast cancer patients.
@en
type
label
Aberrant PTPRO methylation in ...... mes in breast cancer patients.
@ast
Aberrant PTPRO methylation in ...... mes in breast cancer patients.
@en
prefLabel
Aberrant PTPRO methylation in ...... mes in breast cancer patients.
@ast
Aberrant PTPRO methylation in ...... mes in breast cancer patients.
@en
P2093
P2860
P356
P1433
P1476
Aberrant PTPRO methylation in ...... mes in breast cancer patients.
@en
P2093
Hui-lin Wang
Li-kuang Xiong
Rong-cheng Luo
Shao-ying Li
Yu-li Chen
P2860
P2888
P356
10.1186/1471-2156-15-67
P577
2014-06-11T00:00:00Z
P5875
P6179
1037142896